Literature DB >> 24079378

Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013.

R A Perera1, P Wang, M R Gomaa, R El-Shesheny, A Kandeil, O Bagato, L Y Siu, M M Shehata, A S Kayed, Y Moatasim, M Li, L L Poon, Y Guan, R J Webby, M A Ali, J S Peiris, G Kayali.   

Abstract

We describe a novel spike pseudoparticle neutralisation assay (ppNT) for seroepidemiological studies on Middle East respiratory syndrome coronavirus (MERSCoV) and apply this assay together with conventional microneutralisation (MN) tests to investigate 1,343 human and 625 animal sera. The sera were collected in Egypt as a region adjacent to areas where MERS has been described, and in Hong Kong, China as a control region. Sera from dromedary camels had a high prevalence of antibody reactive to MERS-CoV by MERS NT (93.6%) and MERS ppNT (98.2%) assay. The antibody titres ranged up to 1,280 and higher in MN assays and 10,240 and higher in ppNT assays. No other investigated species had any antibody reactivity to MERS-CoV. While seropositivity does not exclude the possibility of infection with a closely related virus, our data highlight the need to attempt detection of MERSCoV or related coronaviruses in dromedary camels. The data show excellent correlation between the conventional MN assay and the novel ppNT assay. The newly developed ppNT assay does not require Biosafety Level 3 containment and is thus a relatively high-throughput assay, well suited for large-scale seroepidemiology studies which are needed to better understand the ecology and epidemiology of MERS-CoV.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24079378     DOI: 10.2807/1560-7917.es2013.18.36.20574

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  176 in total

1.  A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates.

Authors:  Karuppiah Muthumani; Darryl Falzarano; Emma L Reuschel; Colleen Tingey; Seleeke Flingai; Daniel O Villarreal; Megan Wise; Ami Patel; Abdullah Izmirly; Abdulelah Aljuaid; Alecia M Seliga; Geoff Soule; Matthew Morrow; Kimberly A Kraynyak; Amir S Khan; Dana P Scott; Friederike Feldmann; Rachel LaCasse; Kimberly Meade-White; Atsushi Okumura; Kenneth E Ugen; Niranjan Y Sardesai; J Joseph Kim; Gary Kobinger; Heinz Feldmann; David B Weiner
Journal:  Sci Transl Med       Date:  2015-08-19       Impact factor: 17.956

2.  Systematic Review of Important Viral Diseases in Africa in Light of the 'One Health' Concept.

Authors:  Ravendra P Chauhan; Zelalem G Dessie; Ayman Noreddin; Mohamed E El Zowalaty
Journal:  Pathogens       Date:  2020-04-20

3.  Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection.

Authors:  Kristen E Pascal; Christopher M Coleman; Alejandro O Mujica; Vishal Kamat; Ashok Badithe; Jeanette Fairhurst; Charleen Hunt; John Strein; Alexander Berrebi; Jeanne M Sisk; Krystal L Matthews; Robert Babb; Gang Chen; Ka-Man V Lai; Tammy T Huang; William Olson; George D Yancopoulos; Neil Stahl; Matthew B Frieman; Christos A Kyratsous
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-29       Impact factor: 11.205

4.  Development and validation of a rapid immunochromatographic assay for detection of Middle East respiratory syndrome coronavirus antigen in dromedary camels.

Authors:  Daesub Song; Gunwoo Ha; Wissam Serhan; Yassir Eltahir; Mohammed Yusof; Farouq Hashem; Elsaeid Elsayed; Bahaaeldin Marzoug; Assem Abdelazim; Salama Al Muhairi
Journal:  J Clin Microbiol       Date:  2015-01-28       Impact factor: 5.948

5.  Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.

Authors:  Julie Dyall; Christopher M Coleman; Brit J Hart; Thiagarajan Venkataraman; Michael R Holbrook; Jason Kindrachuk; Reed F Johnson; Gene G Olinger; Peter B Jahrling; Monique Laidlaw; Lisa M Johansen; Calli M Lear-Rooney; Pamela J Glass; Lisa E Hensley; Matthew B Frieman
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

6.  Seroepidemiology of Middle East respiratory syndrome (MERS) coronavirus in Saudi Arabia (1993) and Australia (2014) and characterisation of assay specificity.

Authors:  M G Hemida; R A Perera; R A Al Jassim; G Kayali; L Y Siu; P Wang; K W Chu; S Perlman; M A Ali; A Alnaeem; Y Guan; L L Poon; L Saif; M Peiris
Journal:  Euro Surveill       Date:  2014-06-12

7.  Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution.

Authors:  Xian-Chun Tang; Sudhakar S Agnihothram; Yongjun Jiao; Jeremy Stanhope; Rachel L Graham; Eric C Peterson; Yuval Avnir; Aimee St Clair Tallarico; Jared Sheehan; Quan Zhu; Ralph S Baric; Wayne A Marasco
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

8.  Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response.

Authors:  Kam-Leung Siu; Man Lung Yeung; Kin-Hang Kok; Kit-San Yuen; Chun Kew; Pak-Yin Lui; Chi-Ping Chan; Herman Tse; Patrick C Y Woo; Kwok-Yung Yuen; Dong-Yan Jin
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

9.  Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection.

Authors:  Arlene Barlan; Jincun Zhao; Mayukh K Sarkar; Kun Li; Paul B McCray; Stanley Perlman; Tom Gallagher
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

10.  Competitive ELISA for the Detection of Serum Antibodies Specific for Middle East Respiratory Syndrome Coronavirus (MERS-CoV).

Authors:  Shuetsu Fukushi
Journal:  Methods Mol Biol       Date:  2020
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.